Sarepta price target raised to $160 from $125 at BTIG

BTIG analyst Yun Zhong raised the firm’s price target on Sarepta to $160 from $125 and keeps a Buy rating on the shares. The company has been "building an increasingly strong case" for FDA approval of SRP-9001, and now with BLA officially accepted by the FDA for filing with a priority review and a PDUFA date of May 29, there is a high probability – almost certainty – for an accelerated approval for the drug by mid-2023, the analyst tells investors in a research note.